Clinical Trial Search

Primary: Cardiac Glucose Uptake in FDG-PET (Fluorodeoxyglucose-Positron Emission Tomography) — 1.0; 0.6; 0.9; 0.8 standardized uptake value (SUV) — p=0.04

Primary: Change in Systemic Vascular Resistance Index (SVRI) to Pulmonary Vascular Resistance Index (PVRI) Ratio (Rp:Rs Ratio) — 0.8; 0.75; 0.61; 0.73 Rp:Rs ratio — p=0.9

Primary: Pulmonary Artery Systolic Pressure. — 58.6; 62.7; 42.8; 57.5 mmHg

Primary: Difference in Ambulatory 6 Minute Walk Distance (6MWD) Pulmonary Artery (PA) Pressures (Systolic, Diastolic, Mean) Between the Post-intervention (iNO+) and…

Primary: Perfused Blood Volume Assessed for a Change in Lung Inflammation Pre and Post Dose Sildenafil Administration — 0.37; 0.42 coefficient of variation — p=<0.05

Primary: Change in Pulmonary Vascular Resistance (PVR) — 0.77; 0.40; -0.39 Woods units — p=0.002

Primary: Change in Mean Pulmonary Artery Pressure (MPAP) — 6.5; 4.3 mmHg

Primary: 6-minute-walk Distance (6MWD) — 330.0; 328.6 meters — p=0.7883

Primary: Change in Exercise Pulmonary Hemodynamics From Baseline to Week 24 — 37.4 mmHg — p=.0008

Primary: Maximum Change From Baseline in Supine Systolic Blood Pressure (SBP) Within 4 Hours Post-dose at Visit 6 (Week 12) — -20.70; -20.20 mmHg

Primary: Number of Participants Experiencing Significant Fluid Retention or Worsening in NYHA Functional Class (FC) up to End-of-treatment — 7; 4; 7; 3 Participants — p=0.3372

Primary: Change From Baseline in Peak Oxygen Uptake (VO2 Max) at 24 Weeks — 1.28 mL/min/kg

Primary: Relative Change From Baseline to Week 12 in Pulmonary Vascular Resistance (PVR). — 0.63; 0.98 ratio — p=0.0001

Primary: Absolute Change in Right Ventricular Ejection Fraction — 10.4 % RVEF — p=0.028

Primary: Change in 6 Minute Walk Test — 7.00; 16.60; 16.00; 4.90 Meters walked in 6 minutes

Primary: Change From Baseline in Right Ventricular Stroke Volume (RVSV) to Week 26 — 15.17 milliliters (mL)

Primary: Transthoracic Echocardiogram (ECHO)-Based Change in the Tricuspid Annular Plane Systolic Excursion (TAPSE) Measurement — 2.244; 2.244; 2.300; 2.212 mm

Primary: Ventilation/Perfusion Mismatch — 1.2 difference in right shift (kPa) — p=0.02

Primary: Observed Mean (Std Err) for % Difference Between VMS and MRI. — 4.80; 1.76; 2.03 Percent difference

Primary: Mean Pulmonary Arterial Pressure Change From Baseline — -1.0; -0.73 mmHg

Primary: 6 Minute Walk Distance — 230 meters

Primary: Change in Pulmonary Vascular Resistance — 7.1 percent difference from baseline

Primary: Changes in RV Function — 7.56 percentage

Primary: Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 24, as Measured by Right Heart Catheterization (RHC) — 35; -28; -21; 6 dyne*sec/cm^5 — p== 0.214

Primary: Dose-limiting Toxicities — 0; 0; 0; 0 Participants

Primary: Concentration of Matrix Metalloproteinase 2 and 9 Enzymes — 89289.89; 86548.72; 205707.83; 152911.57 ng/ml — p=<0.05

Primary: Mean Pulmonary Artery Pressure Measured by Right Heart Catheterization — -2.4; -4.7 mmHG

Primary: Changes From Baseline in Peak Exercise Mean Pulmonary Artery Pressure (mPAP), Transpulmonary Pressure Gradient (TPG), and Pulmonary Capillary Wedge Pressure (PCWP)…

Primary: Pulmonary Vascular Resistance (PVR) — 64; 119; 67; 46 dyn*sec/cm^5

Primary: Base Study: Change From Baseline in Pulmonary Vascular Resistance (PVR) at 24 Weeks — -27.6; -168.4; -258.9; 802.0 dynes*sec/cm^5 — p=0.0030